NEW YORK – Molecular diagnostics firm Vikor Scientific has made a strategic investment in California-based Quantgene to accelerate the commercialization of Quantgene's Serenity, a personalized preventive medicine service that includes the use of whole-genome sequencing, artificial intelligence-informed liquid biopsy cancer screening, and other in-depth health profiling.
The companies made the announcement on Wednesday during the SCBIO 2021 annual meeting. Financial details of the deal were not disclosed.
Quantgene describes Serenity as a direct-to-consumer concierge medical service that is intended to improve users' health by assessing their genetic and other disease risk factors, providing regular reanalysis based on evolution of the medical literature. This is coupled with serial blood-based monitoring for early signs of cancer.
In their announcement, the partners said that they also plan to add to the current service with additional liquid biopsy products including minimal residual disease and recurrence monitoring assays for patients with an already diagnosed cancer, as well as unspecified companion diagnostics.